

A Charity registered

in England and Wales - charity Number: 1156927

in Scotland - charity Number: SC048960

Annual Report and Financial Statements

Period from 1 June 2021 to 31 May 2022

The trustees are pleased to present their annual report together with the financial statements of the charity for the year ended 31st May 2022.

The financial statements comply with the Charities Act 2011, the Constitution of The Humanimal Trust, and Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and the Republic of Ireland (FRS 102).

CHAIR'S REPORT

As we enter the final year of our current five-year strategy, looking back on 2021/22 has provided us with an opportunity to reflect on how much has changed since the strategy was agreed in 2018. A global pandemic, war in Europe, a global fuel crisis, a cost of living crisis and four different Prime Ministers in six years were not on anybody's SWOT analysis. The impact on us all as individuals – some far more acute than others – and on Society as a whole, was inevitable. It has affected charities in different ways, too. Some have deservedly experienced a new wave of support for their work. Others, like Humanimal Trust, seeking longer term change and less focused on urgent grass roots impact, have found it more challenging to break through into public consciousness, not least because opportunities to meet the public face to face have been extremely limited.

With that in mind, it is all the more heartening for Humanimal Trust trustees to be able to report a successful year and a healthy level of income, allowing us to plan for the future with much greater confidence. 2021/22 was also the year Humanimal Trust began to engage with a number of significant new corporate and individual supporters, whom we hope will remain with us for the long term. With more of that kind of support we can really forge forward with One Medicine, so that humans and animals benefit reciprocally from medical research and not at the cost of an animal's life. We'd particularly like to thank Leucillin and Corrigan Gore for their enthusiasm, support and commitment.

In late 2021 we published our first impact report, looking back at the first seven years of the charity's life. We are very demanding of ourselves. Nothing will be enough until One Medicine becomes the norm. However, our impact report showed that we should be proud of the progress we have made as a new, small charity. The last year has been the same. We asked a lot of ourselves and despite having to focus on ensuring the charity was financially fit as we emerged from the pandemic, we can still point to many achievements. As we look forward to a new strategy period from 2023, we are excited about a new-found focus in the way we drive forward our agenda. Our five work areas spell out I-CARE, which sums up the way we feel, our supporters feel, and we hope everybody will one day feel about One Medicine:

- Influence We care about bringing together everyone who cares about One Medicine to create a road map for change in public policy, in education and at the clinical coalface.
- **Collaboration** We care about creating opportunities for human and veterinary professionals and students to learn from one another by demonstrating One Medicine at work.
- Awareness We care that people should know and understand the benefits of One Medicine for humans and animals, about non-animal alternatives to laboratory models supporting animal as well as human medicine and to how much human and animal medicine can learn from one another's clinical practice saving time, money and lives.
- **Research** We care about research funding it, facilitating it, shouting about it that could benefit humans and animals without using laboratory animal models.

• **Education** – We care about learning – every child learning about the connections between humans and animals; veterinary and human medical students learning with and from one another; practitioners and clinicians learning continuously from their peers.

We believe that education is key to One Medicine. Only by learning about the similarities between humans and animals from the earliest stage, to collaboration in the most advanced science and clinical practice, will we change the world for good. For that to happen we must ensure that the best research, clinical practice and learning, benefiting both humans and animals, are funded, encouraged and promoted. The past year has given us a chance to regroup, refocus and renew our commitment. We are determined that the next year and beyond will see One Medicine move firmly into the mainstream of consciousness, research and clinical practice. I'd like to conclude by thanking the tireless staff of Humanimal Trust, our volunteers, supporters, advisors and my fellow trustees, who collectively continue to steer the charity through challenging times towards our long-term goals and aspirations.

I Care – We Care – Do you?

Professor Roberto La Ragione

Chair of the Board of Trustees

OUR IMPACT IN 2021/22 THE YEAR IN REVIEW

a. Highlights

Humanimal Trust One Medicine Day Symposium: In May 2021, Humanimal Trust's inaugural global One Medicine Symposium: *Stronger Together*, brought together more than 100 scientists, clinicians and students from around the world to discuss practical ways forward for One Medicine. The event provoked contacts and potential collaborations and helped to build the global One Medicine network. A working group built around a number of participants has continued to collaborate and support Humanimal Trust's own developing work.

One Medicine Day Seminar: In May 2022, attracting interest from more than 100 people worldwide and picking up the thread of the symposium, the One Medicine Day Seminar: *One Medicine in Action* focused on:

- What joined up approaches or collaboration would look like in action and how to provide more opportunities
- How to raise greater awareness of the benefits of One Medicine approaches

Like the symposium before it, the seminar created new connections, broadened the One Medicine Network and encouraged participants to think more proactively about how to convey the distinctive history, definition and purpose of One Medicine, whilst encouraging collaborative engagement with those from One Health or One Welfare backgrounds.

Humanimal Hub: The Humanimal Hub, our free online forum and interactive space where leading minds in human and animal medicine can meet, collaborate and share knowledge and research, continued to grow in scale and influence. 250 people are now approved members, up from 204 in 2020/21.

Humanimal Pledge: We continued to engage with ever wider audiences through the Humanimal Trust Pledge for One Medicine, with over 20,000 signatories now committed to champion One Medicine.

INTERACT: We announced a memorandum of understanding with Oklahoma State University (OSU) College of Veterinary Medicine's Institute for Translational and Emerging Research in Advanced Comparative Therapy (INTERACT), which aims to promote research into the development of new therapeutic and diagnostic platforms for use in both veterinary and human medicine.

UTOMIC: We established a working relationship with the Utrecht Translational One Medicine Innovation Centre (UTOMIC), which aims to accelerate One Medicine Research, helping human and veterinary patients, while at the same time reducing the need for laboratory animals in biomedical and veterinary research.

One Health Lessons: We participated in activities organised by One Health Lessons, which develops lessons for children and adults so that they can understand the inextricable connection between human health and the health of animals, plants, and the environment.

Network of influence: We continued to broaden contact with scientists, academics and educationalists in Europe, N. and S. America and Australasia, promoting opportunities for collaboration and learning.

Research impact:

Humanimal Trust has supported two projects, primarily funded by Action Medical Research, with two grants of £5,000 each. The first of these completed in 2022 while the second is ongoing.

The first study, led by Professor Hall-Scraggs at University College London focuses on juvenile idiopathic arthritis (JIA). Patients with JIA have a disease which causes inflammation of their joints. This leads to pain, joint deformity, disability and reduced quality of life. There are newer 'biologic' drugs now available that suppress joint inflammation, but these are expensive and can have side effects, the most serious being life-threatening infection. Magnetic resonance imaging (MRI) scans can show inflammation of joints. By measuring inflammation in patients with juvenile idiopathic arthritis the study was able to help optimise their treatment by showing how much inflammation is present and whether it changes with treatment.

The second Action Medical Research study, considering infection prevention and its impact on antimicrobial resistance in critically ill children, led by Dr Nazima Pathan, Lecturer in Paediatric Intensive Care at the University of Cambridge, is ongoing.

Media and Publications: This year a significant expansion in media coverage was achieved. The Trust's activities attracted the attention of local and digital media (both lay and specialist). Professional and academic publications featured Humanimal Trust on a more regular basis, such as British Medical Journal (BMJ), Animal Therapy Magazine and Nursing Times.

Events: We organised or took part in the following events to meet the public and spread the One Medicine message – Paws for a Picnic Autumn Fair, VET Festival, three DogFest events, and talks were given to 13 community groups totalling approximately 450 attendees throughout the year. There were also high-profile speaking engagements at a conference organised by INTERACT (Professor Roberto La Ragione) and the International Veterinary Students Association (Jo Blake).

Education: Emerging from both the One Medicine Symposium and ongoing strategic development of an educational programme, Humanimal Trust committed to the long-term development of a One Medicine curriculum and began development of pilot activities with educational establishments.

Legacies: A total of five major legacies were notified or received during 2021/22, totalling just over £540,000.

Paws for a Picnic: The Trust's first mass participation event was launched in Spring 2021, with the significant and very welcome support of Lyvlee Ltd. via *Leucillin*, backed by an ongoing digital advertising and PR campaign.

Building donor support: 2021/22 saw a concerted effort to build relationships with corporate, trust and individual givers whose commitment to One Medicine was represented by significant levels of support. Thanks to Quantity Surveyors, Corrigan Gore who sponsored an engagement dinner at Mark's Club, Mayfair as well as looking at other ways of supporting the charity.

A supporter event was also held at Fitzpatrick Referrals, hosted by our founder Noel Fitzpatrick. This event also signalled the launch of a new giving scheme for supporters able to make higher-level gifts, known as Humanimal Visionaries and Patrons.

Ongoing development of existing fundraising schemes continued, including the Champions regular giving scheme, in memory giving, the newly launched One Medicine Lottery and *Ripples* scheme.

Podcast: First Humanimal Trust podcast series launched - Humanimal Connection. Success laid groundwork for second series in 2022/3 with over 250 listens and more than 30% outside the UK.

b. 2021/22 Specific Objectives and Impact

Our specific objectives for 2021-22 remained rooted in our 5-year strategic objectives. However, with the impact of Covid19, economic and cost of living uncertainty, Humanimal Trust, like many charities, had to remain agile and focused on ensuring immediate continuity of income and expenditure. This meant that, although the 5-year objectives and associated KPIs remained in place, some were reviewed, revised or rescheduled over the course of the year.

Our indicators of success are sometimes relevant to more than one work-stream. For instance, sign-ups to either the Pledge or the Humanimal Hub are indicators of progress in influence, awareness, and collaboration. Where this is the case, progress is recorded under one, but not all of the five work-streams and cross-referenced where appropriate.

Principal focus areas in 2021/22 were:

- Awareness building with professional, public and specialist funding audiences
- Income generation
- Partnership building (for both income generation and scientific/educational purposes)
- Network building and influence marketing

I - Influence

5-Year Strategic Objective:

As the evidence for One Medicine grows, we will continue to share knowledge with policy-makers and politicians to inform better legislation.

2021/22 Objective:

Establish credible and effective presence and relationships with regulatory and membership veterinary, medical and associated bodies

This remains an area we wish to develop further as resources allow. Invitations for us to participate in events organised by other organisations have increased, as has the willingness of other organisations to take part in

our own. While we cannot yet point to clear evidence of having changed national or international policy frameworks to reflect a commitment to One Medicine specifically, we can see that the language of collaboration and reciprocity, as well as an apparent commitment to reduce, refine and replace laboratory animal models, are slowly beginning to reflect Humanimal Trust's aspirations.

Humanimal Trust wishes to be seen as the centre of a network of influence for One Medicine. A growing number of individuals and organisations are now part of our global network. The Humanimal Hub, Humanimal Pledge, podcast series and PR programme all reinforce this area of activity. In 2022/23 we aim to increase our engagement with policy makers, including the All Party Group on Animal Welfare and other all-party or backbench committees in the UK parliament.

C - Collaboration

Strategic objective 2:

We aim to demonstrably increase collaboration between medical and veterinary professionals, to maximise value and minimise delays in progress.

2021/22 Objectives:

- Continue to raise awareness of The Hub and use it to generate active collaboration
- Seek new partnership collaborations to further visibility and influence
- Maximise mutual benefit of collaboration with Action Medical Research
- Fuel debate and raise expectations for collaboration

As above, Hub membership and activity is also a measure of success in terms of demonstrating collaboration.

Hub members increased to 250, below the target of 300 but a healthy increase on 204 in 2020/21. The Hub is encouraging conversations and we are aware of at least one active collaboration that began as a result of an introduction on the Hub. The Hub as also been important in the building of networks and partnerships as referred to elsewhere in this report.

As well as encouraging collaboration between others, it is important for Humanimal Trust to build both formal and informal long-term relationships with like-minded organisations with whom joint efforts can push forward the One Medicine agenda. In the past year, three relationships in particular stand out: UTOMIC, INTERACT and One Health Lessons, the latter two of which are now subjects of Memoranda of Understanding with Humanimal Trust. We envisage a range of collaborations from network-sharing and event participation to joint promotional and perhaps research-related activity.

Initial conversations regarding possible joint activities also began with Rest Easy Method (mental health education), Montessori (educational outreach), Royal National Orthopaedic Hospital (exploring possible opportunities for collaboration) and various publishing companies.

Our support for two studies, principally funded by Action Medical Research, continued to demonstrate our ongoing commitment to research collaboration. These are described in more detail below.

A - Awareness

5-year Strategic Objective:

We aim to measurably increase public, professional and political awareness, understanding and acceptance of One Medicine.

2021/22 *Objective:*

 Demonstrate continued increase in awareness of Humanimal Trust and One Medicine among key target audiences (public, veterinary and medical)

Awareness objectives overlap with a number of others, so indicators of success are shared in some cases. For professional audiences, particular focus was given to expanding membership of the Humanimal Hub, our free online forum and interactive space for doctors, vets, nurses, researchers, GPs and related professionals. Although growth in membership is steady rather than rapid, the quality of membership and the resulting expansion of a One Medicine network of influence with Humanimal Trust at the centre, is extremely valuable. Greater emphasis is now being placed on encouraging Hub members to collaborate, participate in One Medicine-related activities, volunteer for the Trust and encourage peers to join.

Membership of the Hub covers a wide range of professions including:

Vet surgeon/vet therapist:16%Researcher:9%Nurse:9%Vet student:8%Bioscience/bioengineering:7%Scientist:5%Staff/vols:4%Vet nurse:4%GP:3%Medical student:2%Science Lecturer:2%Specialist/Consultant surgeon:2%	Other:	26% (rounded)
Nurse: 9% Vet student: 8% Bioscience/bioengineering: 7% Scientist: 5% Staff/vols: 4% Vet nurse: 4% GP: 3% Medical student: 2% Science Lecturer: 2%	Vet surgeon/vet therapist:	16%
Vet student: 8% Bioscience/bioengineering: 7% Scientist: 5% Staff/vols: 4% Vet nurse: 4% GP: 3% Medical student: 2% Science Lecturer: 2%	Researcher:	9%
Bioscience/bioengineering: 7% Scientist: 5% Staff/vols: 4% Vet nurse: 4% GP: 3% Medical student: 2% Science Lecturer: 2%	Nurse:	9%
Scientist: 5% Staff/vols: 4% Vet nurse: 4% GP: 3% Medical student: 2% Science Lecturer: 2%	Vet student:	8%
Staff/vols: 4% Vet nurse: 4% GP: 3% Medical student: 2% Science Lecturer: 2%	Bioscience/bioengineering:	7%
Vet nurse: 4% GP: 3% Medical student: 2% Science Lecturer: 2%	Scientist:	5%
GP: 3% Medical student: 2% Science Lecturer: 2%	Staff/vols:	4%
Medical student: 2% Science Lecturer: 2%	Vet nurse:	4%
Science Lecturer: 2%	GP:	3%
	Medical student:	2%
Specialist/Consultant surgeon: 2%	Science Lecturer:	2%
	Specialist/Consultant surgeon:	2%
Pharmacist: 1%	Pharmacist:	1%

Talks to professional and science audiences also restarted, with talks given to the International Veterinary Students Association, INTERACT and an increasing number of invitations to speak at a range of conferences and events being received for the current year.

For lay audiences, traditional, social and other digital media continued to prove successful for building general awareness, along with continuation of our successful events and talks programmes, which were rejuvenated from late 2021 following relaxing of Covid restrictions.

Public talks began to take place again from late in 2021. To the end of May 2022, 13 talks were given to approximately 450 attendees, some leading to coverage in local media.

Our website remained a core point of contact with 3,320 visits between One Medicine Day, 6 May 2021 through until 6 May 2022, a 50% increase on the same period for the prior year..

Our first series of Podcasts was launched - Humanimal Connection — which began to establish a new audience-connection and an opportunity to explore more deeply the ways in which One Medicine is reflected in everything from conservation or protecting wild animals from poachers, to marine biology and food production. A second series has been commissioned for 2022/23.

Media coverage increased steadily this year, and along with it, audience-reach, particularly in scientific, specialist and local media. More than 40 titles in total covered Humanimal Trust activities, a total reach of 13,124,260 readers. Although specific audience reach has not been measured previously, we know this is a significant improvement in visibility for the trust year on year. Coverage included:

- Animal Therapy Magazine
- British Medical Journal (BMJ)
- Nursing Times
- Vet Times
- theknowledgereview.com
- Recruitment.Gov
- www.vetclick.com
- www.veterinary-practice.com
- www.vetnurse.co.uk
- www.vetreport.net
- www.vetsurgeon.org
- Argus (Brighton)
- Bath Chronicle
- Birkenhead News
- Chichester Observer
- The Chronicle
- Derby Telegraph
- Devon Daily
- Dorset Echo
- Exeter Daily
- Express and Star (Wolverhampton)
- Hull Daily Mail
- Ilford Recorder
- Leicester Mercury
- Liverpool Echo

- Newcastle Upon Tyne Journal
- South Wales Echo
- Western Mail
- Western Morning News
- Whitchurch Herald
- Wirral Globe
- Wishaw Press
- Index Digital
- www.choosevourevent.co.uk
- www.eventbrite.co.uk
- www.inyourarea.co.uk
- www.list.co.uk
- www.tdpelmedia.com
- www.wherecanwego.co.uk
- Visit Surrey
- Essential Surrey
- nigeriannewsdirect.com
- Voice of Nigeria

TOTAL REACH: 13,124,260

Social media reach:

Facebook: 11,000K followers
 Twitter: 7,043 followers
 Instagram: 1,506 followers
 Linkedin: 237 followers
 Youtube: 476 subscribers

R - Research

Strategic Objective 4:

We aim to improve and accelerate the growing understanding of the complex interactions between animal and human biological characteristics, the similarities between them and the opportunities arising from them.

We want to repaint the landscape in which medicine is researched and received; redefining the language of respectful interaction between species at the clinical coalface.

2021/22 Objectives:

- Fund at least one significant new research proposal with One Medicine ethos
- Fund at least one Proof of Concept award
- Launch and deliver first One Medicine Challenge and Learning Awards
- Maximise mutual benefit of grant-linked donation to Action Medical Research and consider second-year funding.
- Build One Medicine evidence base

The difficult circumstances of the pandemic limited our ability to fund new research projects but that did not prevent us from actively promoting research relevant to One Medicine ethos through the Humanimal Hub or from laying the groundwork for a series of new research initiatives that are now planned for 2022/3. Recruitment to the new Science Committee continued and the infrastructure for new research calls began to be put in place. New research plans for 2022/23 include undergraduate projects chosen through a 'sandpit' event, as well as proof of concept studies, education and creative awards.

Of the two studies funded by Action Medical Research and supported by Humanimal Trust, one was completed and one is still active:

Professor Hall-Craggs' work at University College London focused on juvenile idiopathic arthritis (JIA). Patients with JIA have a disease which causes inflammation of their joints. This leads to pain, joint deformity, disability and reduced quality of life. There are newer 'biologic' drugs now available that suppress joint inflammation, but these are expensive and can have side effects, the most serious being life-threatening infection. Magnetic resonance imaging (MRI) scans can show inflammation of joints. By measuring inflammation in patients with juvenile idiopathic arthritis we aim to help optimise their treatment by showing how much inflammation is present and whether it changes with treatment.

The project report gave the following headlines (edited):

- We developed an artificial intelligence assisted method of extracting and quantifying the areas of inflammation in the sacroiliac joints (SIJs) of routine scans of SIJ. We have written a paper on this and have submitted it to a medical journal.
- We are developing a colour coded picture which shows areas of inflammation in joints and bone. This can be used to show whether inflammation is getting worse (red) or getting better (green). These are known as

parametric response maps and we have some preliminary work from our SIJ scans which have demonstrated proof of principle.

- We have completed the largest ever study of whole body imaging in juvenile arthritis patients which has shown much more unsuspected inflammation that anticipated. This study is now being written up for publication but has been reported at scientific meetings (and the work won a prize).
- We have run a Virtual Clinic to get an idea of whether the whole body MRI scans would affect the way that doctors treat their patients. This has been completed by 2 consultant rheumatologists and this shows that the provision of whole body scans would likely alter management decisions in up to 30% of patients with juvenile arthritis. Some of these would get more treatment, and some less. Some would have their appointment intervals changed or have additional/fewer imaging tests.
- We have disseminated the results of the studies we have conducted widely. We have had presentations at the British Society of Rheumatology, British Society of Paediatric and Adolescent Rheumatology, International Society of Magnetic Resonance in Medicine, and the British Society for Spondyloarthritis.

This research can also produce transferable data which could be directly applicable in a veterinary setting.

The second Action Medical Research study, considering infection prevention and its impact on antimicrobial resistance in critically ill children (led by Dr Nazima Pathan, Lecturer in Paediatric Intensive Care at the University of Cambridge) is ongoing.

E - Education

Strategic Objective:

We aim to inspire everyone to take the One Medicine message forward as a credible vision of hope for future generations of humans and animals.

2021/22 *Objectives:*

- Increase awareness of and engagement with Humanimal Trust and One Medicine among children and young people
- Increase awareness and engagement with Humanimal Trust and One Medicine among future vets, doctors and animal welfare professionals

Although this area of work was not able to move forward as quickly as we would have liked because of resource limitations and the impact of the pandemic, much progress was made internally. A significant commitment was made by the charity to ensure that an educational focus should characterise everything that we do. A long term change in mindset towards One Medicine depends on addressing the relationship between human and animal health and wellbeing at every stage of learning along with an acceptance that lasting change is generational and depends on us being able to reach out to the next generations of doctors, vets, researchers and caring professionals. From pre-school to continuous professional development, a lifelong One Medicine curriculum is our ultimate aim and during the latter stages of 2021/22, we agreed our first school pilot activities for teenage

pupils and put in place plans for new learning materials for younger pupils. A knowledge exchange scheme for professional learning is now also in planning mode and is hoped to be launched by the end of 2022.

During the year our ability to give talks at universities and colleges or to engage with student societies was limited, with digital contact and promotion of Humanimal Hub membership the main source of engagement. However for younger children, promotion of new learning materials with Montessori ensured our commitment to all age groups continued.

Enabling Objective - Income

2021/22 Objectives:

- Achieve sustainable income level and replenish reserves
- Increase total income and broaden range of sustainable income streams

A truly challenging year was principally characterised by careful ongoing control of expenditure, selective investment in fundraising and awareness activities and maintenance of staff wellbeing. The successful beginnings of corporate partnerships with both Leucillin and Corrigan Gore, along with the charity's first two major donor engagement events, the launch of a mid-level giving programme and the ongoing promotion of our Paws for a Picnic participation event, all signalled a commitment to invest wisely in sustainable income streams.

Regular income from donors and from a range of challenge, digital and other streams such as a new lottery, Amazon Smile, Facebook fundraising, in memory giving and unclaimed fund initiatives all continued to contribute to steady income through the year. A few events towards the end of the financial year and local fundraising activities also began to re-emerge as long-term income opportunities.

However, it was as a result of a combination of long term investment in both the Humanimal Trust brand and Noel Fitzpatrick's own profile, specific legacy marketing and good stewardship, that a number of major gifts and legacies made the real difference to the charity's ability to plan more confidently for the future.

Legacies and major gifts:

During 2021/22 two legacies were received in full, totalling just over £90,000. A substantial interim payment of £450,000 on a third legacy was also received during the year. As at 31 May 2022 three further legacies were in progress. Legacies remain a valuable source of income to the charity and legacy marketing is an important element of our fundraising activity, but equally we seek a more balanced set of income streams in the longer term.

Overall the £348,000 income target for the year was exceeded by almost the same amount, ending the year with total income of just under £695,000 and reserves replenished to a level that allows more confident planning in 2022/23.

Enabling Objective - Team Development:

2021/22 *Objective:*

Continue to increase staff and volunteer capacity to deliver business plan and strategy

In a second year so significantly affected by COVID-19, the well-being of staff and volunteers as well as their performance and development was important to the trustees and home-based working was the norm throughout the year, with other support offered as appropriate. Some specific personal development work was undertaken by both permanent staff members and ongoing support and development for volunteers was a year-round priority, with regular online meetings and socials as well as newsletters and a volunteer survey all running through the year. A combination of targeted voluntary and consultancy support provided support, advice and specialist skills where needed. The first ever team day, while taking place digitally, helped to ensure a more coherent approach to long-term planning.

A commitment was made by trustees to support effort to build a more sophisticated UK-wide volunteer structure with volunteers grouped regionally and sharing knowledge and skills more effectively whilst building a sense of 'team' between otherwise quite isolated volunteers. The appointment of a volunteer coordinator, themselves a volunteer, reinforced this commitment to support the volunteer network more actively. A greater focus on seeking volunteers with specialist skills, especially in education and science, also began to take shape during the year as an explicit recognition of the need to expand reach without the resource to expand the staff complement enormously.

Enabling objective - Governance:

2021/22 Objectives:

- Continue to develop and review governance and policy framework
- Continue to develop diversity and capacity of Board and Committees
- Appoint further members to Science Committee and activate
- Appoint further members to Expert Panel and activate
- Review contribution of Income Generation, Finance and Audit Committee

Humanimal Trust's Board continued to reinforce its commitment to good governance and continuing to learn and improve its own knowledge and expertise in this area. The annual trustee review meant that each trustee had the opportunity to share privately with the Chair, their views on their own contribution and that of the Board as a whole. The organisation's governance manual, policies and procedures are reviewed and approved by trustees every year.

Recruitment to the Science Committee restarted, with a view to having sufficient members in time for the first planned research calls in 2022/23. Several members have already accepted invitations to join and a number of prospective members identified.

The Income Generation Finance and Audit Committee continued to monitor financial health during the year, providing advice to the Board through the Treasurer.

The Board itself met more regularly and thanks are due to all trustees, although we were sorry to say goodbye to Dr. Mike Uglow who stepped down after six years' service as a trustee, including two as chair. However, he will continue to make a contribution to the charity through membership of the Science Committee.

c. 2022/23 Looking forward:

We recognise the need to present One Medicine consistently through an education 'lens'. Our absolute priority is to change understanding at every level from pre-school to professional training and development of the relationship between human and animal health and the need for collaboration and reciprocity of benefit to humans and animals.

With that 'lens' in mind, our focus for the next twelve months at least is very clearly on four key areas of activity which will run through all five of our I-CARE strategic workstreams:

- Focused awareness building with professional, lay, youth, trade and specialist funder audiences
- Partnerships, networks and collaborations: placing Humanimal Trust at the centre of a One Medicine web of influence
- Education
- Research funding, engagement and influencing activity based on achieving a wider scope of visibility and outcomes from limited resources

In turn these will be made possible by two core 'enabling' or 'capacity-building' activities:

- Volunteer strategy, with a focus on building a more coherent pattern of local integrated volunteer networks around the UK.
- Income generation, with a focus on building a broad range of sustainable income streams, with a greater emphasis on building up major donor support and volunteer fundraising leadership alongside more established forms of individual giving.

Staff and governance development will also remain underlying priorities.

HUMANIMAL TRUST IN A NUTSHELL

Who We Are

Humanimal Trust drives collaboration between vets, doctors and researchers so that all humans and animals benefit from sustainable and equal medical progress but not at the expense of an animal's life. This is One Medicine.

What we do:

I care - We care - Do you?

- We care about the health and wellbeing of both humans and animals.
- We care about groundbreaking medical progress that benefits humans and animals alike.
- We care that the value of a life should not depend on species.
- We care about all human and veterinary medical and research professionals learning from and with each other, throughout their education and career, to benefit all humans and animals.
- We care about collaborating to get the very best results for patients, regardless of their species.
- We care about reciprocity humans and animals should benefit equitably from medical progress.
- We care that more needs to be done to make animal testing obsolete in both human and veterinary medicine.
- We care about the health of all humans and animals everywhere.
- We care about One Medicine.

Influence – We care about bringing together everyone who knows and cares about One Medicine to create a road map for change in public policy and at the clinical coalface.

Collaboration – We care about creating opportunities to bring together human and veterinary professionals and students to learn from one another by demonstrating One Medicine at work.

Awareness – We care that more people should know and understand the benefits of One Medicine for humans and animals, about non-animal alternatives to experimental models supporting progress in both human and animal medicine, and how much human and animal medicine can learn from one another's clinical practice.

Research – We care about research – funding it, encouraging it, supporting it, shouting about it – that could benefit humans and animals without the use of experimental animal models.

Education – We care about learning – we care that every child should learn about the connections between humans and animals; about veterinary and human medical students learning together and from one another; about professionals learning continuously from their peers.

How we do it

We care about prompting the right conversations between the right people. We start them, facilitate them and make sure they continue. We are accessible, inclusive and collaborative – and we care about catalysing change in thought and action.

We care about building a One Medicine community; a network of influence with Humanimal Trust at its heart. We invite healthcare and research students and professionals to come to our free digital meeting space, the Humanimal Hub, to connect and learn so that humans and animals both benefit from the sharing of knowledge.

We care about building the evidence base for One Medicine; we listen, we gather, we share research, ideas and stories. Such evidence is the firm foundation for a credible vision of hope that One Medicine will one day become the norm.

We care about showing both the authority and pragmatism that come from our experience and the confidence that comes from our passion and belief. We work with integrity. We defuse professional confrontation, build bridges and seek to instil a spirit of compassion, respect and mutual benefit.

History

Humanimal Trust was established in May 2014 by Professor Noel Fitzpatrick, known globally as a ground-breaking orthopaedic-neuro veterinary surgeon. As a vet he experienced personally the deep divide between human and animal medicine and saw how unfair this was. Frustrated by the lack of opportunities to share what he was learning from day to day practice, or to benefit from relevant learning from human medicine, he decided to create the platform himself. This laid the foundations for the work the Trust does today, removing barriers and seeking to close the divide between human and animal medicine. Since those beginnings, the Trust has started to establish a powerful evidence base and to build understanding of both the principle and the potential of One Medicine. This evidence informs mechanisms to reduce, refine and replace laboratory animal tests. By studying naturally occurring disease, we will make more rapid progress. Based in Godalming, Surrey, Humanimal Trust is a registered charity in both England and Wales, and in Scotland, influencing worldwide.

Why One Medicine?

As far back as Aristotle in Ancient Greece, convergence between human and animal physiology was a normal part of science. Divergence began in the nineteenth century but an increasing focus on the welfare, rights and conservation of animals in recent times has led to renewed interest. Human and veterinary healthcare can and should advance hand in hand. Technological advances in the diagnosis and analysis of naturally occurring disease mean that for the first time in history the end point of the study of disease does not need to involve the death of an animal. A two-way street between human and veterinary medicine is both possible and necessary for humans and animals to benefit equitably from cutting edge advances. One Medicine recognises that progress in both human and veterinary medicine depends on sharing technologies and research that recognise overlapping biological characteristics.

What we believe?

We believe a world is possible, where humans and animals benefit equally and at the same time from advances in medicine. This is reciprocity.

We believe that equitable advances in both human and animal medicine can be achieved more quickly, if there is closer collaboration and mutually beneficial learning. This is One Medicine. We believe and advocate that this approach will lead to progressively fewer laboratory animal tests until one day they become obsolete.

We believe in sponsoring only research that helps - and learns from - animals being treated for naturally occurring disease – not the use of experimental animal models.

We believe that technological advances in the diagnosis and analysis of naturally occurring disease mean that for the first time in history the end point of the study of disease does not need to involve the death of an animal. Even with experimental therapies, such as for cancer, if we share what we already know from veterinary clinical practice and consensual clinical trials with animals, we have the potential to save the lives of both humans and animals without the need to sacrifice a healthy animal's life.

However, there are still too few validated non-animal test alternatives for assessing safety of new drugs and medical devices for human use and laboratory animal testing is still required by Law. This has to change. Our intent is that with One Medicine such testing will become obsolete.

In the meantime, we are committed to - and strongly advocate investment in - the 3 R's: a reduction in animal testing, refinement and replacement of animal tests wherever possible. We also believe in a fourth R: reciprocity. Most current laboratory animal testing is for the sole, often arguable benefit of humans and not the animal concerned or its species.

Currently too little is invested in developing treatments for animals. If veterinary clinical trials were linked to human drug development, resources could be saved and treatments developed more quickly for both humans and animals.

We believe that the world would be fairer and more respectful for humans and animals if One Medicine were more widely understood and delivered.

One Medicine has a very specific focus on reciprocity. It differs from One Health. One Health seeks better health through addressing risks at the interface between humans, animals and their environments. While One Health may intend to help animals alongside humans, in reality priority is too often given only to human health and wellbeing.

With support and information from Humanimal Trust, we believe everyone can contribute to One Medicine, through giving, advocating, learning or educating. Anyone can talk to their vet or their doctor about One Medicine.

Our purpose is not to endorse any particular lifestyle, including vegetarian or vegan, nor are we an animal rights organisation. These are personal choices and beliefs and not part of One Medicine.

We believe we all share responsibility for creating a fairer society, with better opportunities to benefit equitably from medical progress for humans and animals. However, we believe the greatest responsibility lies with vets, doctors, researchers and scientists worldwide. There is currently no formal platform for the sharing of knowledge between human and veterinary medicine. We seek to change that.

We believe that if we miss this opportunity we will all pay the price in wasted time, wasted money, and the wasted lives of both humans and animals.

FINANCIAL REVIEW

Income for the year ended 31st May 2022 amounted to £694,878 (£156,110 in 2020/21).

The charity had a net surplus of unrestricted income over expenditure for the year of £385,673 (deficit of (£74,013) in 2020/21) and a net surplus of restricted income over expenditure of £37,715 (£7,285) in 2020/21) resulting in total funds of £453,921 carried forward as at 31st May 2022.

Investment powers and policy

To date, funds have been held on current account at the charity's bank, have not been actively invested and no investment income has been earned. The trustees will monitor the cash balances of the charity and will make decisions as to the appropriateness of this policy going forward.

Reserves Policy and Going Concern

Reserves are required to bridge the gaps between the spending and the receipt of income, and to cover unforeseen circumstances. The charity will normally seek to hold sufficient unrestricted reserves to cover six months of operations, which will enable its work to continue uninterrupted.

The charity has more than sufficient funds to cover six months of outgoings at the present time and as such the trustees present the accounts on a going concern basis.

REFERENCE AND ADMINISTRATIVE DETAILS

Charity number: Registered in England and Wales, number 1156927

Registered in Scotland, number SC048960

Principal Office: Eashing Barns, Halfway Lane, Eashing, Surrey GU7 2QQ, United Kingdom.

Our advisors: Accountants:

Radford & Sergeant Limited, Building 3, Watchmoor Park, Camberley GU15 3YL.

Bankers:

CAF Bank, Kings Hill Avenue, West Malling, Kent, ME19 4JQ.

Trustees

The trustees serving during the year and since the year-end were as follows:

Prof. Roberto La Ragione (Chair since 11 Oct 2018)	Appointed for three years to August 2019
	Re-appointed for three years to August 2022
	Re-appointed for three years to August 2025
Prof. Noel Fitzpatrick	Appointed indefinitely
Ms Dineke Abbing	Appointed for three years to May 2017
	Re-appointed for three years to May 2020
	Re-appointed for three years to May 2023
Mr. Mike Uglow	Appointed for three years to November 2018
	(Chair from 14 th Sept 2016 to 11 Oct 2018)
	Re-appointed for three years to November
	2021
	Resigned October 2021
Dr. Ben Marshall	Appointed for three years to July 2019
	Re-appointed for three years to July 2022
	Re-appointed for three years to July 2025
Miss Anna Radford	Appointed for three years to October 2025

STRUCTURE, GOVERNANCE AND MANAGEMENT

Governing Document

Humanimal Trust is a Charitable Incorporated Organisation (CIO) governed by a Constitution dated 6th May 2014 and as last amended 28th May 2019, and is registered as a charity with the Charity Commission. Membership of the CIO is restricted to the serving trustees.

Appointment of trustees

As set out in the Constitution there must be a minimum of three trustees. Apart from the first charity trustees, every trustee must be appointed for a term of three years by a resolution passed at a properly convened meeting of the charity trustees. In selecting individuals for appointment as charity trustees, the charity trustees must have regard to the skills, knowledge and experience needed for the effective administration of the CIO.

Trustee induction and training

The charity trustees will make available to each new charity trustee, on or before his or her first appointment:

- (a) a copy of the current version of the Constitution; and
- (b) a copy of the CIO's latest Trustees' Annual Report and financial statements.

New trustees undergo an orientation meeting to brief them on: their legal obligations under charity and company law, the Charity Commission guidance on public benefit, and inform them of the content of the Constitution, the committee and decision-making processes, the business plan and recent financial performance of the charity.

Trustees are encouraged to attend appropriate external training events where these will facilitate the undertaking of their role.

Organisation

The board of trustees, which can have up to twelve members, administers the charity and normally meets quarterly at a minimum. The board may from time to time establish sub-committees and three such committees had been active since July 2016: (1) for matters relating to medical and science review, (2) for matters relating to fundraising and marketing, and (3) for matters relating to finance and audit. In 2020 the latter two committees merged into one Income Generation, Finance and Audit committee (IGFA).

Related parties and co-operation with other organisations

None of the trustees receives remuneration or other benefit from their work with the charity. Any connection between a trustee or senior manager of the charity and a university or research institution, sponsor, donor or commercialisation partner must be disclosed to the full board of trustees in the same way as any other contractual relationship with a related party.

Pay policy for senior staff

All trustees provide their time freely and no trustee received remuneration. However, trustees are entitled to receive reimbursement of expenses incurred on behalf of the charity.

Staff remuneration is set and reviewed by the trustees in accordance with resourcing strategy and financial status.

Risk management

The trustees have a risk management strategy which comprises:

- an annual review of the principal risks and uncertainties that the charity faces;
- the establishment of policies, systems and procedures to mitigate those risks identified in the annual review; and
- the implementation of procedures designed to minimise or manage any potential impact on the charity should those risks materialise.

Financial sustainability has been a continued principal area of risk for the charity. In light of the impact of the Covid-19 pandemic, a 'revival' strategy was implemented in 2020. Income from legacies in 2021-22 has replenished reserves allowing for more confident planning whilst maintaining a prudent approach.

Trustees' responsibilities in relation to the financial statements

The charity trustees are responsible for preparing a trustees' annual report and financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Charity law requires the charity trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources, including the income and expenditure, of the charity for that period. In preparing the financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to assume that the charity will continue in business.

The trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charity and to enable them to ensure that the financial statements comply with charity law. They are also responsible for safeguarding the assets of the charity and hence taking reasonable steps for the prevention and detection of fraud and other irregularities.

The trustees are responsible for the maintenance and integrity of the charitable and financial information included on the charity's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

By order of the Board of Trustees

Professor Roberto La Ragione, Chair

Date: 21 December 2022

INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF THE HUMANIMAL TRUST

I report on the financial statements of Humanimal Trust for the year ended 31 May 2022 on pages 24 to 31.

Respective responsibilities of trustees and examiner

The charity's trustees are responsible for the preparation of the accounts. The charity's trustees consider that an audit is not required for this year under section 144(2) of the Charities Act 2011 (the Charities Act) and that an independent examination is needed. It is my responsibility to:

- examine the accounts under section 145 of the Charities Act,
- to follow the procedures laid down in the general Directions given by the Charity Commission (under section 145(5)(b) of the Charities Act) and to state whether particular matters have come to my attention.

Basis of independent examiner's statement

My examination was carried out in accordance with the general Directions given by the Charity Commission. An examination includes a review of the accounting records kept by the charity and a comparison of the accounts presented with those records. It also includes consideration of any unusual items or disclosures in the accounts, and seeking explanations from the trustees concerning any such matters. The procedures undertaken do not provide all the evidence that would be required in an audit and, consequently, no opinion is given as to whether the accounts present a 'true and fair' view and the report is limited to those matters set out in the statement below.

Independent examiner's statement

In connection with my examination, no matter has come to my attention:

- 1. which gives me reasonable cause to believe that in any material respect, the requirements:
- to keep accounting records in accordance with section 130 of the Charities Act; and
- to prepare accounts which accord with the accounting records and comply with the accounting requirements of the Charities Act

have not been met; or

2. to which, in my opinion, attention should be drawn in order to enable a proper understanding of the accounts to be reached.

Date: 21 December 2022

Kim Swain MA (Oxon) FCA Radford & Sergeant Limited Chartered Accountants Building 3 Watchmoor Park Camberley Surrey GU15 3YL

STATEMENT OF FINANCIAL ACTIVITIES (INCLUDING INCOME AND EXPENDITURE ACCOUNT) FOR THE PERIOD FROM 1 JUNE 2021 TO 31 MAY 2022

	Note	Unrestricted Funds 2022	Restricted Funds 2022	Total Funds	Total Funds
Income from:		£		£	£
Donations and legacies	3, 4	647,841	45,000	692,841	151,651
Charitable activities	6	2,037		2,037	1,010
Other income	7				3,449
Total Income		649,878	45,000	694,878	156,110
Expenditure on:					
Raising funds	8	102,369		102,369	78,948
Charitable activities	8	161,836	7,285	169,121	143,890
Total Expenditure		264,205	7,285	271,490	222,838
Net income/(expenditure) and net					4
movement in funds		385,673	37,715	423,388	(66,728)
Reconciliation of funds:					
Total funds brought forward		23,248	7,285	30,533	97,261
Total funds carried forward		408,921	45,000	453,921	30,533

BALANCE SHEET AS AT 31 MAY 2022

	Note	Total funds 2022 £	Total funds 2021 £
Fixed assets: Intangible assets Tangible assets	10 11	413 543	- 1,504
Current assets: Stock	12	916	893
Debtors	13	11,551	9,972
Cash at bank and in hand Total current asse	ets	463,467 475,934	36,888 47,753
Liabilities:		,	·
Creditors: Amounts falling due within one year	14	22,969	18,724
Net current asse	ets	452,965	29,029
Total net assets		453,921	30,533
The funds of the charity:			
Restricted income funds		45,000	7,285
Unrestricted funds		408,921	23,248
Total charity fun	ds	453,921	30,533

Approved by the Board of Trustees on 21 December 2022 and signed on its behalf by

NOTES TO THE FINANCIAL STATEMENTS

1 Accounting Policies

The principal accounting policies adopted, judgements and key sources of estimation uncertainty in the preparation of the financial statements are as follows:

a) Basis of preparation

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) - (Charities SORP (FRS 102) and the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

Humanimal Trust meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy note(s).

b) Preparation of the accounts on a going concern basis

The accounts are prepared on a Going Concern basis.

c) Income

Income is recognised when the charity has entitlement to the funds, any performance conditions attached to the item(s) of income have been met, it is probable that the income will be received and the amount can be measured reliably.

Income from government and other grants, whether 'capital' grants or 'revenue' grants, is recognised when the charity has entitlement to the funds, any performance conditions attached to the grants have been met, it is probable that the income will be received and the amount can be measured reliably and is not deferred.

For legacies, entitlement is taken as the earlier of the date on which either: the charity is aware that probate has been granted, the estate has been finalised and notification has been made by the executor(s) to the Trust that a distribution will be made, or when a distribution is received from the estate. Receipt of a legacy, in whole or in part, is only considered probable when the amount can be measured reliably and the charity has been notified of the executor's intention to make a distribution. Where legacies have been notified to the charity, or the charity is aware of the granting of probate, and the criteria for income recognition have not been met, then the legacy is treated as a contingent asset and disclosed if material.

d) Fixed assets

Intangible assets relate to the trade mark costs of the Humanimal Trust logo for charitable purpose and are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation at 10% straight line annually plus any accumulated impairment losses.

Tangible fixed assets are stated at their historic cost price less accumulated depreciation. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for use. The asset's residual values, useful lives and depreciation methods are reviewed if there is an indication of significant change since the last reporting date. Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life:

Office equipment - 20% straight line, and Computer equipment - over 3 years.

e) Fund accounting

Unrestricted funds are available to spend on activities that further any of the purposes of the charity. Restricted funds are donations which the donor has specified are to be solely used for particular areas of the Trust's work or for specific research projects being undertaken by the Trust. As at 31 May 2022 the Trust's funds consisted of £408,921 of unrestricted funds (2020/21: £23,248) and £45,000 of restricted funds (2020/21: £7,285).

f) Expenditure and irrecoverable VAT

Expenditure is recognised once there is a legal or constructive obligation to make a payment to a third party, it is probable that settlement will be required and the amount of the obligation can be measured reliably.

Expenditure is classified under the following activity headings:

- Expenditure on raising funds; includes the cost of goods sold, payment processing fees, plus fundraising specific materials, supplies and travel.
- Expenditure on charitable activities; includes website design and maintenance, fees of independent examiners, delivery of strategic objective activities.

Governance is included in expenditure on charitable activities. The Trust initially identifies the cost of its support functions. It then identifies those costs which relate to the governance function. Having identified its governance costs, the remaining support costs together with the governance costs are apportioned between the charitable activities undertaken in the year. Irrecoverable VAT is charged as a cost against the activity for which the expenditure was incurred.

g) Stock

Stock relates to merchandising items and is valued at the lower of cost and net realisable value, after allowance for obsolete and slow moving items.

h) Debtors

Trade and other debtors are recognised at the settlement amount due after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

i) Cash at bank and in hand

Cash at bank and cash in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account. Cash in transit is included.

2 Legal status of the Trust

The Trust is a Charitable Incorporated Organisation and has no share capital.

3 Income from donations and legacies

The Trust benefits greatly from the involvement and enthusiastic support of its volunteers. In accordance with FRS 102 and the Charities SORP (FRS 102), the economic contribution of general volunteers is not recognised in the accounts.

During the year to 31 May 2022 the Trust gratefully received £74,018 from general donations, mostly online, plus £78,500 from corporate and charity donations. The Trust furthermore received unrestricted income from legacies totalling £495,323.

	2022	2021
	£	£
General Gifts (including Gift Aid reclaimable)	74,018	61,651
Corporate and Charity Donations	78,500	5,000
Legacies	495,323	35,000
	647,841	101,651

4 Restricted Income

The Trust received £45,000 of restricted income in the year ended 31st May 2022 (£50,000 in 2020/21). This sum formed part of a major legacy and is restricted for use towards the cost of work that aims to contribute to the prevention, treatment or cure of cancer. The balance of restricted income brought forward from the prior year was expended in full towards the cost of the Humanimal Hub.

	2022	2021
	£	£
Balance brought forward	7,285	-
Restricted income received	45,000	50,000
Expenditure incurred	(7,285)	(42,715)
Balance carried forward	45,000	7,285

Analysis of staff costs, trustee remuneration and expenses, and the cost of key management personnel

Throughout the year the Trust had the continued support from its Development Manager and Science Officer. All other activities of the charity were carried out by volunteers, freelance contractors or consultants and there were no other remunerated members of staff.

The charity trustees were not paid nor received any other benefits from employment with the Trust. No charity trustee received payment for professional or other services supplied to the charity.

Support costs are directly allocated to activities where possible. The remuneration of the Development Manager is allocated 40% to raising funds and the balance to charitable activities. Remuneration of the Science Officer is allocated to charitable activities.

6 Charitable activities

The Trust generated income from merchandise sales during the year of £775 (£1,010 in 2020/21) and net proceeds of £1,262 (£nil in 2020/21) from the One Medicine Lottery scheme.

7 Other Income

The Trust did not receive any Government grants in the year (£3,449 in 2020/21).

8 Expenditure

Principal expenditure included £102,369 to cover the cost of raising funds (£78,948 in 2020/21) and £169,921 towards the cost of delivery of the Trust's charitable objectives (£143,890 in 2020/21). The latter included £41,746 towards the ongoing development and maintenance of the Humanimal Hub (£54,519 in 2020/21).

Independent examiner's fees	2022	2021
	£	£
Independent examination	2,600	2,400
Accounts preparation	1,120	1,080
	3,720	3,480

9 Corporate Taxation

The charity is exempt from tax on income and gains falling within section 505 of the Taxes Act 1988 or section 252 of the Taxation of Chargeable Gains Act 1992 to the extent that these are applied to its charitable objects.

10 Intangible Assets

	Trademarks	Totals
	£	£
COST		
At 1 June 2021	-	-
Additions	420	420
At 31 May 2022	420	420
DEPRECIATION		
At 1 June 2021	-	-
Charge for year	7	7
At 31 May 2022	7	7
NET BOOK VALUE		
At 31 May 2022	413	413
At 31 May 2021	-	

11 Tangible Assets

	Office equipment	Computer equipment	Totals
	£	£	£
COST			
At 1 June 2021 Additions	1,632	3,708	5,340
At 31 May 2022	1,632	3,708	5,340
	·	<u> </u>	
DEPRECIATION			
At 1 June 2021	927	2,909	3,836
Charge for year	326	635	961
At 31 May 2022	1,253	3,544	4,797
NET BOOK VALUE			
At 31 May 2022	379	164	543
At 31 May 2021	705	799	1,504

12 Stock

	2022	2021
	£	£
Fundraising merchandise	-	346
General merchandise	916	547
	916	893

13 Debtors

The Debtors balance of £11,551 as at 31 May 2022 is made up of prepaid costs in regards the Humanimal Hub and database management along with a small balance on the Trust's Paypal account.

Debtors	2022	2021
	£	£
Sundry debtors	32	1
Prepayments	11,519	9,971
	11,551	9,972

14 Creditors

The Creditors balance of £22,969 as at 31 May 2022 was made up of trade creditors and income tax, national insurance and pension contributions due in June 2022, along with accrued cost for services received but not yet billed and residual research grant funding committed to but not yet paid pending completion of the project.

Creditors	2022	2021
	£	£
Trade creditors	12,148	2,276
Taxes and NI	1,219	1,360
Other creditors	450	444
Accrued expenses	9,152	14,644
	22,969	18,724

15 Related Parties

There were no related party transactions during the year.